N
GYRE icon

Nuveen’s Gyre Therapeutics GYRE Stock Holding History

Nuveen’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,594
Closed -$129K – 3280
2025
Q2 		$129K Buy
+17,594
New +$154K ﹤0.01% 3233
2021
Q2 		– Sell
-14,777
Closed -$559K – 3447
2021
Q1 		$559K Buy
14,777
+4,091
+38% +$187K ﹤0.01% 3074
2020
Q4 		$505K Buy
10,686
+407
+4% +$17.6K ﹤0.01% 3042
2020
Q3 		$332K Hold
10,279
– – ﹤0.01% 3060
2020
Q2 		$453K Buy
+10,279
New +$483K ﹤0.01% 2939

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen's GYRE Position: Q3 2025 in Review

Nuveen sold out of Gyre Therapeutics (GYRE) in Q3 2025, closing a stake of 17,594 shares — an estimated $129K sold.

Nuveen first reported a position in GYRE in Q2 2020 and held it in 5 quarters. The position peaked at $559K in Q1 2021. 48 funds tracked by Wall St. Rank hold GYRE as of Q3 2025.

  • Nuveen reported no remaining Gyre Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Nuveen sold 17,594 Gyre Therapeutics shares in Q3 2025, an estimated $129K.
  • Nuveen first reported a position in Gyre Therapeutics in Q2 2020 and held it in 5 quarters.
  • Nuveen's Gyre Therapeutics position peaked at $559K in Q1 2021.
  • 48 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2025.

Based on Nuveen's 13F filing for Q3 2025, filed 12 Nov 2025.